Anti-OCIAD1 Antilichaam

OCIAD1 was first identified by immunoscreening of an ovarian carcinoma cDNA expression library with ascites fluid from ovarian cancer patients (PMID: 11162530) . OCIAD1 has been reported as a key player in ovarian cancer cell adhesion, as well as a key player in generating ovarian cancer recurrence (PMID: 18328549; 20515946) . In addition to its roles in cancer, OCIAD1 participates in maintaining stem cell potency by regulating the Jak/STAT pathway (PMID: 23972987) . Several alternatively spliced forms of OCIAD1 gene have been identified. The longest form (1.4 kb) is predicted to encode for a 27.6 kDa protein of 245 amino acids. This antibody detects OCIAD1 with an apparent molecular weight of ~35 kDa as has been demonstrated by several researches (PMID: 27345969; 27345976) .

Boster Bio Anti-OCIAD1 Antibody catalog # A10406-2. Tested in WB, IHC, ICC, IF, IP, ELISA applications. This antibody reacts with Human.

TPA018; Ovarian cancer immunoreactive antigen domain containing 1; OCIA domain-containing protein 1; OCIA domain containing 1; OCIA

OCIAD1

Q9NX40

Human

E.coli-derived human OCIAD1 recombinant protein (Position: G3-W243) .

WB, IHC, ICC, IF, IP, ELISA

Immunogen affinity purified.

500 μg/mL

Liquid

12 months from date of receipt, -20°C as supplied. 6 months 2 to 8°C after reconstitution. Avoid repeated freezing and thawing.

https://www.bosterbio.com/msds?sku=A10406-2

OCIA domain containing 1

OCIA domain-containing protein 1

500 μg/mL antibody with PBS,0.02% NaN3, 1 mg BSA and 50% glycerol.